Posts

Showing posts from August, 2022

Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung Cancer

  Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung Cancer   Health Canada approved nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer prior to surgery. Nivolumab (Opdivo) plus platinum-doublet chemotherapy has been approved by Health Canada for the treatment of certain patients with resectable non–small cell lung cancer, according to Bristol Meyers Squibb. The approval was based on results from the phase 3 CheckMate 816 trial (NCT02998528), in which neoadjuvant nivolumab plus chemotherapy resulted in a 37% reduction in risk of disease progression, recurrence, or death vs chemotherapy alone among patients with resectable NSCLC (HR, 0.63; 97.38%, 0.43-0.91;  P  = .005). The median event-free survival (EFS) with nivolumab/chemotherapy was 31.6 months vs 20.8 months with chemotherapy alone. Improvement in the rate of pathologica...

Scientists unlock potential for a small cell lung cancer blood test

  Doctors could one day diagnose and characterise early stage small cell lung cancer (SCLC) with a simple blood test thanks to a transatlantic study led by CRUK Manchester Institute Cancer Biomarker Centre researchers at the University of Manchester with a team at Memorial Sloan Kettering Cancer Center in New York published in Nature Cancer. The study focussed on a new sensitive blood test to detect, characterise and monitor Small Cell Lung Cancer (SCLC), the most aggressive form of lung cancer. SCLC is a fast-growing type of cancer that can rapidly spread to other parts of the body through a process called metastasis. Most small SCLC patients, representing 10-15% of all lung cancer cases, are diagnosed late with advanced metastatic disease and few survive beyond 1 to 2 years.  However, of the minority of patients with SCLC who are diagnosed very early and have surgery, 6 out of 10 can live for 5 years or more. The research team developed a new method to analyse blood samples ...

Orthobiologics: how regenerative medicine can make a difference in orthopedic surgery

Challenges in conventional orthopedic treatments You never know when you might need to see an orthopedic surgeon. From cradle to casket, accidents and injuries are an inevitable part of life, with your joints worse off for it. Even if you can avoid accidents, wear and tear in your joints can lead to arthritis, with an estimated 150,000 knee and hip replacements performed in the US every year, predicted to triple by 2040. While the young and fit can recover from injuries with conventional treatment, we might find our joints don't respond the same way as we age. Tissue such as cartilage, ligaments, and tendons have very little capacity to regenerate and heal by themselves, which worsens as we age. We often resort to joint replacement and invasive procedures to fix our joints when our bodies cannot. Traditionally the choice is between conservative management – physical therapy, mobility aids, steroid injections, and surgical procedures, including joint replacement. Conservative measur...

Why Shaping Workforce For Future Decades Isn’t Just About Wages, Marketing For SanStone

  Industry leaders looking to boost staffing numbers in 2022 and beyond can no longer sit on the sidelines expecting workers to join the sector simply based on a company’s marketing efforts or increased wages. Instead, those at the helm of nursing home companies should take an active role in getting young people introduced to the sector as soon as possible — such as setting up summer internships for teenagers. That’s according to Jennifer Robinson, who ascended to the president role at SanStone Health and Rehabilitation last July. “As a company we’re making strides to start building those interactions and relationships as early as elementary ages. It’s fundamental, I believe, to help our youth feel comfortable in a skilled nursing setting,” Robinson said recently on an episode of the Skilled Nursing News Rethink  podcast .  SanStone has also bolstered its workforce by focusing on internal growth and the creation of succession plans. That planning led Robinson to the role ...

US Market Trends For Computer-Assisted & Robotics-Assisted Surgery

  In the medical industry, adoption of new cutting-edge technology is slow compared to other industries, such as the automotive industry. 1  Computer-assisted and robotic-assisted surgery (CAS and RAS, respectively) have been around for decades, yet a small percentage of procedures performed take advantage of the innovative solutions available on the market today. In coming years, the number of procedures using robotics and surgical navigation is predicted to increase at a double-digit rate year over year to reach over 6 million procedures by 2028. 2  This rise in CAS and RAS can be attributed to the predicted increase in the utilization of navigation systems and robotic devices as more companies launch new or next-generation systems for assisted surgery. Reasons For Slow CAS And RAS Adoption Some argue that using CAS and RAS is not worth the time and monetary investment, as using this technology often increases procedure planning time and reduces the number of procedures...

Philips chief exits in wake of fallout from medical device recall

  The chief executive of Dutch company Philips has left the business in the wake of a costly recall of faulty medical devices that led to a profit warning. The health technology company said on Tuesday that Frans van Houten would be replaced by Roy Jakobs, head of its connected care division, in mid-October. Van Houten’s third term as chief executive was scheduled to end in April next year. The Amsterdam-based group said the supervisory board and van Houten “have agreed that with the end of his third term in sight, the time is right for the change in leadership”. Shares in Philips, which were trading above €41 late last year, rose 2 per cent to €19.89 on Tuesday. Van Houten’s sudden departure comes after the company had to recall or repair 5.2mn devices in June last year. Philips had found a faulty component in the devices, which were primarily used to assist the breathing of patients suffering from sleep apnoea. The Dutch group subsequently issued a profit warning in January and l...

Gene therapy trial markedly cuts bleeding risk in haemophilia B patients

  A new gene therapy has dramatically cut the risk of bleeding in people with the rare condition haemophilia B, experts have said. Researchers  found  that a single injection of the gene therapy, called FLT180a, removed the need for people to inject themselves weekly with clotting factors. The study was led by experts from University College London (UCL), the Royal Free hospital in London and the biotechnology company Freeline Therapeutics. Haemophilia is a rare condition that affects the blood’s ability to clot. It is usually inherited and mostly affects men. Normally, when a person cuts themselves, clotting factors mix with blood cells called platelets to make the bleeding stop. But people with haemophilia are lacking clotting factors and are at risk of heavy bleeding. About 85% of people with haemophilia  have haemophilia A , caused by a lack of the blood-clotting factor VIII, while haemophilia B is caused by a deficiency of factor IX. People with haemophilia B ne...

USA – Overview of Prothrombin Complex Concentrate Industry and Healthcare Statistics in 2022

Image
The global   Prothrombin Complex Concentrate (PCC) market size  was valued at USD 695.3 million in 2019 and is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6 % during the forecast period Abstract Left ventricular assist devices (LVADs) require careful therapeutic anticoagulation with warfarin to prevent pump thrombosis. However, the best method to reverse warfarin for elective LVAD conversion surgery with massive bleeding remains unclear. We report the case of a 39-year-old Japanese man who was administered a four-factor prothrombin complex concentrate (4F-PCC) as warfarin reversal when he underwent conversion surgery from paracorporeal LVAD to implantable LVAD. 4F-PCC with co-administration of vitamin K reduced the international normalized ratio and R time in TEG6s (Haemonetics Corporation, USA) immediately. The effect was prolonged, and good hemostasis was achieved. 4F-PCC with vitamin K provided good hemostasis in our patient; therefore, 4F-PCC co...

Disposable Medical Gloves Growth and Technological Advancement in United States

Image
  The   Disposable Medical Gloves Market  is projected to drop from USD 11.68 billion in 2020 to USD 11.52 billion in 2027 at a CAGR of -0.19% in the 2020-2027 period. There are many more warehouses just like it still in operation today in Thailand -- trying to cash in on the demand for medical-grade nitrile gloves, which exploded with the coronavirus pandemic. And they're boxing up millions of these sub-standard gloves for export to the United States, and countries around the world amid a global shortage that will take years to ease.  A months-long CNN investigation has found that tens of millions of counterfeit and second-hand nitrile gloves have reached the United States, according to import records and distributors who bought the gloves -- and that's just the tip of the iceberg. Criminal investigations are underway by the authorities in the US and Thailand. Experts describe an industry riddled with fraud, with one of them -- Douglas Stein -- telling CNN that nitr...

Drug Delivery Systems Commercialization & Industry Trends Shaping 2022 | United States

Image
The global   drug delivery systems market   size was USD 26.08 billion in 2019 and is projected to reach USD 45.20 billion by 2027, exhibiting a CAGR of 6.8% during the forecast period. Introduction Drug delivery has the potential to have a tremendous impact on treatment of retinal diseases. There are a large number of drugs that are reasonably effective to treat retinal conditions, but those drugs are limited by delivery issues such as the need to have the molecule cross the blood–eye barrier, be present for long times, or the need to mitigate side-effects. The challenges of having drugs at a physiologically relevant concentration for extended periods or in a localized delivery system are challenges that can be solved with drug delivery technology, whether it is using cellular delivery systems, microelectromechanical (MEMs)-based devices, polymer matrices, or gene delivery systems. Get a Sample Copy of the Report at –  https://www.fortunebusinessinsights.com/enquiry...

North America Home Infusion Therapy Size, Scope and Forecast

Image
  The global   home infusion therapy market   size was valued at USD 27.25 billion in 2019 and is projected to reach USD 86.89 billion by 2027, exhibiting a CAGR of 2.2% during the forecast period. Home Infusion Therapy Services Home infusion therapy involves the intravenous or subcutaneous administration of drugs or biologicals to an individual at home.  The components needed to perform home infusion include the drug (for example, antivirals, immune globulin), equipment (for example, a pump), and supplies (for example, tubing and catheters). Likewise, nursing services are necessary to train and educate the patient and caregivers on the safe administration of infusion drugs in the home. Visiting nurses often play a large role in home infusion. Nurses typically train the patient or caregiver to self-administer the drug, educate on side effects and goals of therapy, and visit periodically to assess the infusion site and provide dressing changes. The home infusion ...

North America Anti-Inflammatory Drugs Size, Scope and Forecast | Use Key Players

Image
  The global   anti-inflammatory drugs market size  stood at USD 93.88 billion in 2019 and is projected to reach USD 191.42 billion by 2027, exhibiting a CAGR of 9.3% during the forecast period According to a new study from UTHealth Houston and other institutions, an anti-inflammatory drug may have the ability to treat systemic inflammation and brain damage in patients with severe COVID-19 and greatly lower their risk of dying. A group of researchers led by Louise D. McCullough, MD, PhD, professor and Roy M. and Phyllis Gough Huffington Distinguished Chair in the Department of Neurology at UTHealth Houston, conducted a multi-site, randomised, controlled trial. Aaron M. Gusdon, MD, assistant professor in the Vivian L. Smith Department of Neurosurgery with McGovern Medical School at UTHealth Houston; H. Alex Choi, MD, associate professor in the department as well. The trial’s findings were released in Science Translational Medicine today. 24 individuals with severe COVID-19...

Skin Cancer Treatment 2022 | North America Regions to Dominate the Global Industry

Image
  The global   skin cancer treatment market size  stood at USD 8.19 billion in 2019 and is projected to reach USD 14.55 billion by 2027, exhibiting a CAGR of 7.5% during the forecast period Skin cancer is a disease in which malignant (cancer) cells form in the tissues of the skin. The skin is the body’s largest organ. It protects against heat, sunlight, injury, and infection. Skin also helps control body temperature and stores water, fat, and vitamin D. The skin has several layers, but the two main layers are the epidermis (upper or outer layer) and the dermis (lower or inner layer). Skin cancer begins in the epidermis, which is made up of three kinds of cells: Squamous cells: Thin, flat cells that form the top layer of the epidermis. Basal cells: Round cells under the squamous cells. Melanocytes: Cells that make melanin and are found in the lower part of the epidermis. Melanin is the pigment that gives...